Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem
NCT ID: NCT01408524
Last Updated: 2014-04-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
184 participants
INTERVENTIONAL
2010-02-28
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Also the investigators seek to determine the effective dose of the antihypertensive drugs and their side effects in Thai population.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Post-Craniotomy Blood Pressure Targets
NCT07093151
Hyperlactatemia During and After Tumorcraniotomy
NCT04410315
Subgaleal Drains in Decompressive Craniectomies
NCT03777774
Arterial Pressure and Surgical Hemostasis in Elective Neurosurgery.
NCT05874050
Different Intraoperative Blood Pressure Management on Postoperative Cognitive Function in Tumor Patients（PRECISION）
NCT06711432
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diltiazem
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Diltiazem
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Labetalol
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Labetalol
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diltiazem
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Labetalol
2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Bradycardia \< 60 beat/min
* Second or third degree heart block
* Severe asthma or severe COPD
* Brain stem tumor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mahidol University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
busara sirivanasandha
Miss
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Busara - Sirivanasandha, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Anesthesiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
594/2552(EC4)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.